Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rislenemdaz - Cerecor

Drug Profile

Rislenemdaz - Cerecor

Alternative Names: CERC-301; MK-0657

Latest Information Update: 04 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Cerecor; Merck & Co
  • Class Amines; Antidepressants; Antihypotensives; Antiparkinsonians; Esters; Piperidines; Pyrimidines
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Phase I Orthostatic hypotension
  • Discontinued Parkinson's disease

Most Recent Events

  • 01 Jul 2019 Positive efficacy and adverse events data from a phase I trial in Orthostatic hypotension released by Cerecor
  • 01 Apr 2019 Cerecor completes a phase I trial in Orthostatic hypotension in USA
  • 12 Feb 2019 Cerecor has patent protection for rislenemdaz in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top